Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma <i>In situ</i> Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

Abstract

Exemestane reduces proliferation in ER-positive DCIS. Aromatase inhibition is a potential alternative to tamoxifen in patients who have undergone breast conservation for ER-positive DCIS.